Several biotechnology companies highlighted their efforts to align with the U.S. Food and Drug Administration (FDA) during the J.P. Morgan Healthcare Conference this week, following a year marked by regulatory unpredictability that saw some firms face rejections or delayed approvals.
Beam Therapeutics, Cabaletta Bio, PTC Therapeutics, and BridgeBio each reported progress in reaching consensus with the FDA on regulatory pathways for their respective drug candidates. According to H.C. Wainwright analysts, "Regulatory alignment is compressing timelines and improving visibility to value inflections."
However, uncertainty remains in the sector. Atara Biotherapeutics announced Monday that the FDA had rejected its application for Ebvallo in treating a post-transplant complication related to Epstein-Barr virus. The company stated that the agency's decision was "a complete reversal of position." In its letter, the FDA said Atara’s single-arm ALLELE study was “no longer considered to be adequate to provide evidence of effectiveness for accelerated approval,” according to Atara’s announcement. The company further noted that the agency’s “new position is contrary to the FDA’s prior guidance to Atara, the FDA’s alignment with Atara on the clinical trial data set, and the acceptance of the trial design as a single arm study as relevant for this patient population at BLA submission.”
Other companies have faced similar reversals from regulators over recent months. Speaking during a BioSpace webinar in November, BMO Capital Markets analyst Evan Seigerman discussed Replimune's experience after its advanced melanoma candidate RP1 was unexpectedly rejected last July: “Today, they had one set of guidance from FDA with regard to clinical trial design, or how they could have a unique trial design . . . and then all of a sudden, there’s a 180,” Seigerman said. “and it throws everything into a tailspin.”
Beam Therapeutics announced it has agreed with the FDA on an accelerated approval pathway for BEAM-302 in alpha-1 antitrypsin deficiency (AATD). Positive early results were seen in a Phase I/II trial in March 2025 showing genetic correction in this rare disease. The approval pathway will use AAT biomarkers evaluated over 12 months, and Beam plans to enroll about 50 more patients at an optimal dose level.
H.C. Wainwright analysts commented: “We believe this defined regulatory path for BEAM-302 significantly de-risks development.” Beam also expects to file for approval of risto-cel—its cell therapy for sickle cell disease—by late 2026.
Cabaletta Bio has reached agreement with the FDA on new registrational cohort designs using single-arm cohorts for its CD19 CAR T cell therapy rese-cel in systemic lupus erythematosus (SLE) and lupus nephritis (LN). Each cohort will include about 25 patients. The company launched similar cohorts in dermatomyositis and antisynthetase syndrome last December.
William Blair analysts noted: “In our view, Cabaletta continues to execute on advancing rese-cel in multiple indications, as highlighted by the initiation” of this registrational trial.
Cabaletta expects full Phase I/II data from rese-cel studies in SLE, systemic sclerosis (SSc), and myasthenia gravis (MG) by mid-2026.
PTC Therapeutics had both setbacks and successes last year: winning approval for Sephience for phenylketonuria but receiving an FDA rejection for vatiquinone targeting Friedreich’s ataxia due to insufficient evidence of efficacy.
Ahead of CEO Matthew Klein’s presentation at JPM26, PTC reported aligning with the FDA on designing a global Phase III trial for votoplam in Huntington’s disease—a condition where treatment options remain limited—and indicated possible openness from regulators toward accelerated approval given unmet needs.
William Blair analysts said they “view alignment with the FDA on the trial design for votoplam in Hungtinton’s [sic] disease as positive, and look forward to the company sharing additional details regarding the trial’s design and what endpoints could be used to support accelerated approval.”
BridgeBio recorded $146 million revenue growth—a 35% increase quarter-on-quarter—for its ATTR-CM drug Attruby during Q4 2025 according to Truist Securities. On regulatory matters, BridgeBio reported two end-of-Phase II meetings with regulators regarding encaleret (chronic hypoparathyroidism) and ribitol (limb girdle muscular dystrophy type 2I/R9). For ribitol specifically, BridgeBio suggested that interim functional data supported pursuing traditional full approval based on discussions with regulators; new drug applications are expected by mid-2026.
